These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
310 related articles for article (PubMed ID: 33066548)
1. Atorvastatin Augments Gemcitabine-Mediated Anti-Cancer Effects by Inhibiting Yes-Associated Protein in Human Cholangiocarcinoma Cells. Kitagawa K; Moriya K; Kaji K; Saikawa S; Sato S; Nishimura N; Namisaki T; Akahane T; Mitoro A; Yoshiji H Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33066548 [TBL] [Abstract][Full Text] [Related]
2. Angiotensin receptor blockade attenuates cholangiocarcinoma cell growth by inhibiting the oncogenic activity of Yes-associated protein. Saikawa S; Kaji K; Nishimura N; Seki K; Sato S; Nakanishi K; Kitagawa K; Kawaratani H; Kitade M; Moriya K; Namisaki T; Mitoro A; Yoshiji H Cancer Lett; 2018 Oct; 434():120-129. PubMed ID: 30031758 [TBL] [Abstract][Full Text] [Related]
3. Enhanced expression of ten-eleven translocation 1 reverses gemcitabine resistance in cholangiocarcinoma accompanied by a reduction in P-glycoprotein expression. Wang C; Ye H; Zhang L; Cheng Y; Xu S; Zhang P; Zhang Z; Bai J; Meng F; Zhong L; Shi G; Li H Cancer Med; 2019 Mar; 8(3):990-1003. PubMed ID: 30784212 [TBL] [Abstract][Full Text] [Related]
4. Inhibition of FGFR2 enhances chemosensitivity to gemcitabine in cholangiocarcinoma through the AKT/mTOR and EMT signaling pathways. Jaidee R; Kukongviriyapan V; Senggunprai L; Prawan A; Jusakul A; Laphanuwat P; Kongpetch S Life Sci; 2022 May; 296():120427. PubMed ID: 35218764 [TBL] [Abstract][Full Text] [Related]
5. The Upregulation of OCT4 in Acidic Extracellular pH is Associated with Gemcitabine Resistance in Cholangiocarcinoma Cell Lines. Choodetwattana P; Proungvitaya S; Jearanaikoon P; Limpaiboon T Asian Pac J Cancer Prev; 2019 Sep; 20(9):2745-2748. PubMed ID: 31554372 [TBL] [Abstract][Full Text] [Related]
6. SRPK Inhibitors Reduce the Phosphorylation and Translocation of SR Protein Splicing Factors, thereby Correcting Changphasuk P; Inpad C; Horpaopan S; Khunchai S; Phimsen S; Surangkul D; Janvilisri T; Silsirivanit A; Kaewkong W Front Biosci (Schol Ed); 2024 Sep; 16(3):17. PubMed ID: 39344395 [TBL] [Abstract][Full Text] [Related]
7. Cannabidiol exhibits potent anti-cancer activity against gemcitabine-resistant cholangiocarcinoma via ER-stress induction in vitro and in vivo. Pongking T; Thongpon P; Intuyod K; Klungsaeng S; Thanan R; Chaidee A; Charoenram N; Kongsintaweesuk S; Sakonsinsiri C; Vaeteewoottacharn K; Pinlaor S; Pinlaor P BMC Complement Med Ther; 2024 Aug; 24(1):325. PubMed ID: 39215312 [TBL] [Abstract][Full Text] [Related]
8. Anti-Tumor and Chemosensitizing Effects of the CDK Inhibitor Dinaciclib on Cholangiocarcinoma Sungwan P; Kidoikhammouan S; Thonsri U; Saengboonmee C; Wongkham S; Okada S; Seubwai W In Vivo; 2024; 38(5):2284-2293. PubMed ID: 39187317 [TBL] [Abstract][Full Text] [Related]
9. MiR-206 suppresses the deterioration of intrahepatic cholangiocarcinoma and promotes sensitivity to chemotherapy by inhibiting interactions with stromal CAFs. Yang R; Wang D; Han S; Gu Y; Li Z; Deng L; Yin A; Gao Y; Li X; Yu Y; Wang X Int J Biol Sci; 2022; 18(1):43-64. PubMed ID: 34975317 [No Abstract] [Full Text] [Related]
10. Curcumin synergistically enhances the efficacy of gemcitabine against gemcitabine-resistant cholangiocarcinoma via the targeting LAT2/glutamine pathway. Thongpon P; Intuyod K; Chomwong S; Pongking T; Klungsaeng S; Muisuk K; Charoenram N; Sitthirach C; Thanan R; Pinlaor P; Pinlaor S Sci Rep; 2024 Jul; 14(1):16059. PubMed ID: 38992159 [TBL] [Abstract][Full Text] [Related]
11. Dinaciclib, a cyclin-dependent kinase inhibitor, suppresses cholangiocarcinoma growth by targeting CDK2/5/9. Saqub H; Proetsch-Gugerbauer H; Bezrookove V; Nosrati M; Vaquero EM; de Semir D; Ice RJ; McAllister S; Soroceanu L; Kashani-Sabet M; Osorio R; Dar AA Sci Rep; 2020 Oct; 10(1):18489. PubMed ID: 33116269 [TBL] [Abstract][Full Text] [Related]
12. Long non-coding RNA LINC00665 promotes gemcitabine resistance of Cholangiocarcinoma cells via regulating EMT and stemness properties through miR-424-5p/BCL9L axis. Lu M; Qin X; Zhou Y; Li G; Liu Z; Geng X; Yue H Cell Death Dis; 2021 Jan; 12(1):72. PubMed ID: 33436545 [TBL] [Abstract][Full Text] [Related]
13. Plasmalemma vesicle-associated protein promotes angiogenesis in cholangiocarcinoma via the DKK1/CKAP4/PI3K signaling pathway. Wang Y; Yu H; Xie X; Deng T; Ye L; Wu L; Ding X; Yang Z; Zhu Q; Li J; Zheng Y; Yu Z; Chen G Oncogene; 2021 Jun; 40(25):4324-4337. PubMed ID: 34079085 [TBL] [Abstract][Full Text] [Related]
14. A PLCB1-PI3K-AKT Signaling Axis Activates EMT to Promote Cholangiocarcinoma Progression. Liang S; Guo H; Ma K; Li X; Wu D; Wang Y; Wang W; Zhang S; Cui Y; Liu Y; Sun L; Zhang B; Xin M; Zhang N; Zhou H; Liu Y; Wang J; Liu L Cancer Res; 2021 Dec; 81(23):5889-5903. PubMed ID: 34580062 [TBL] [Abstract][Full Text] [Related]
16. The combination of gemcitabine plus an anti-FGFR inhibitor can have a synergistic antitumor effect on FGF-activating cholangiocarcinoma. Ito Y; Yamada D; Kobayashi S; Sasaki K; Iwagami Y; Tomimaru Y; Asaoka T; Noda T; Takahashi H; Shimizu J; Doki Y; Eguchi H Cancer Lett; 2024 Jul; 595():216997. PubMed ID: 38801887 [TBL] [Abstract][Full Text] [Related]
17. Knockdown of cullin 3 inhibits progressive phenotypes and increases chemosensitivity in cholangiocarcinoma cells. Pratummanee K; Kerdkumthong K; Roytrakul S; Tantimetta P; Runsaeng P; Saeheng S; Obchoei S Mol Med Rep; 2024 Nov; 30(5):. PubMed ID: 39239747 [TBL] [Abstract][Full Text] [Related]
18. Quantitative proteomics analysis reveals possible anticancer mechanisms of 5'-deoxy-5'-methylthioadenosine in cholangiocarcinoma cells. Kerdkumthong K; Nanarong S; Roytrakul S; Pitakpornpreecha T; Tantimetta P; Runsaeng P; Obchoei S PLoS One; 2024; 19(6):e0306060. PubMed ID: 38923999 [TBL] [Abstract][Full Text] [Related]
19. Actinidia arguta (Hardy Kiwi) Root Extract Exerts Anti-cancer Effects via Mcl-1-Mediated Apoptosis in Cholangiocarcinoma. Zhao X; Wen F; Wang W; Lu Z; Guo Q Nutr Cancer; 2019; 71(2):246-256. PubMed ID: 30633583 [TBL] [Abstract][Full Text] [Related]
20. Leukemia inhibitory factor protects cholangiocarcinoma cells from drug-induced apoptosis via a PI3K/AKT-dependent Mcl-1 activation. Morton SD; Cadamuro M; Brivio S; Vismara M; Stecca T; Massani M; Bassi N; Furlanetto A; Joplin RE; Floreani A; Fabris L; Strazzabosco M Oncotarget; 2015 Sep; 6(28):26052-64. PubMed ID: 26296968 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]